Up to 15 percent of people with MS are diagnosed with primary progressive multiple sclerosis (PPMS).

The disease is named “primary progressive” because it progresses from the onset of the first (primary) symptoms. PPMS symptoms steadily worsen over time without relapses or remissions, unlike relapsing-remitting multiple sclerosis (RRMS), which is characterized by exacerbations followed by periods of symptom-free remission.

The progression of symptoms in PPMS varies between patients. The disease is called “active” when a patient experiences occasional relapses or there is evidence of new lesions on an MRI. “Not active” or “with progression” means there is evidence that a symptom is worsening over time with or without relapse, or new lesions are shown on an MRI.

People with PPMS have fewer brain lesions and inflammation than people with RRMS. Conversely, people with PPMS usually have more spinal cord lesions than people with RRMS.

PPMS diagnosis

Accurate diagnose of PPMS requires at least three characteristics. The patient must have one year of disease progression (worsening of neurological function without remission), and two additional characteristics that could include a brain lesion that is recognized as typical of MS, two or more lesions of a similar pattern in the spinal cord, or evidence of immune system activity in the central nervous system (shown in an elevated IgG index or an oligoclonal band in the spinal fluid).

PPMS diagnosis can take a long time, especially in cases when neurologic symptoms have just begun. In fact, PPMS diagnosis can take two to three years longer than RRMS diagnosis.

Typically, PPMS is diagnosed between 40 and 60 years old, but earlier diagnosis can happen. The disease affects women and men equally.  People with PPMS usually experience more problems with walking and working, and may require assistance for everyday activities.

Treating PPMS

On March 28 2017, Ocrevus (ocrelizumab) became the first treatment approved by the U.S. Food and Drug Administration (FDA) specifically to treat PPMS. In clinical trials, Ocrevus slowed disease progression in PPMS patients.

Other treatments are still in development. There are ongoing clinical trials (such as NCT02284568NCT01776060 and NCT02913157) assessing various experimental PPMS medications.

People who experience relapses or show evidence of disease activity on an MRI are sometimes prescribed approved RRMS disease-modifying therapies that are made to reduce inflammation in the central nervous system.

There are also ways for PPMS patients to manage the disease, beyond medication. Appropriate exercise and healthy eating habits are important for people with MS. When relapse or worsening of symptoms occur, physical and occupational therapy can help minimize muscle weakness and help restore movement.

Be sure to follow the latest developments on PPMS treatments by following Multiple Sclerosis News Today’s Progressive Multiple Sclerosis Experimental Therapy Tracker.

SMA News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.


Dr. Patricia Coyle at CMSC 2016 Discussing Progressive MS Treatment

#AAN2019 — Ibudilast Slows Brain Atrophy in PPMS But Not SPMS Patients, Phase 2b Trial Shows

Treatment with oral ibudilast slows brain shrinkage in patients with primary progressive multiple sclerosis (PPMS), but not in those with secondary progressive MS (SPMS), according to results of a Phase 2b clinical trial. According to the findings, this could be partially due to faster disease progression in untreated controls with PPMS. The study, “Response to Treatment […]

Roche and pan-Canadian Pharmaceutical Alliance Finalize Ocrevus Negotiations for RRMS and Early PPMS

Roche Canada and the pan-Canadian Pharmaceutical Alliance (pCPA) have completed negotiations ultimately aiming to obtain public funding for Ocrevus (ocrelizumab) as a first-line treatment for adults with relapsing-remitting multiple sclerosis (RRMS) with active disease, and as management strategy for patients with early primary progressive MS (PPMS). Active disease in people with RRMS is defined by […]

MS News that Caught My Eye Last Week: New DMT, Stem Cell Trial, Pediatric MS Treatment Study

FDA Will Review New Drug Application of Diroximel Fumarate for Relapsing Forms of MS The good news: Another disease-modifying therapy (DMT) has taken a step toward approval in the U.S. The discouraging news: It’s another DMT designed to treat relapsing forms of multiple sclerosis. More than a dozen of those treatments are currently available. When […]

#ACTRIMS2019 — Use of Ocrevus at Cleveland Clinic Backs Phase 3 Trial Data

Ocrevus (ocrelizumab) was shown to be a highly effective therapy for people with multiple sclerosis (MS) in real-world clinical practice, according to Brandon Moss, MD, from the Cleveland Clinic. The data was presented in a poster session Feb. 28, at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2019. The poster was titled “Real-World Experience […]

FDA Asked to Place Cannabis-based Therapy for Progressive MS on Fast Track, MMJ Holdings Says

A request for a potential cannabis-based treatment for multiple sclerosis to be given Fast Track designation, speeding its development as it readies to enter clinical testing, is now before the U.S. Food and Drug Administration (FDA), MMJ International Holdings announced. MMJ-001, as this lead candidate is known, aims to treat the spasticity (muscle stiffness) associated with progressive multiple sclerosis. The company is also targeting Huntington’s-associated chorea, […]

Petition Urges NHS England to Make Ocrevus Available for PPMS Patients

More than 21,000 people have signed a petition calling for Ocrevus (ocrelizumab) to be made available by the National Health Service (NHS) in England for people with primary progressive multiple sclerosis (PPMS). According to an MS Trust press release, the letter was signed by the MS Society UK, MS Trust UK, Shift MS, and leading neurologists, […]

RRMS Diagnosed Most Often in Younger Women and PPMS in Older Men, European Study Reports

Women with multiple sclerosis are being diagnosed at younger ages and in greater numbers than men, except for those with primary progressive disease (PPMS), where men 50 or older tend to predominate, a European review study that looked at trends over several decades reports. The study “Age‐dependent variation of female preponderance across different phenotypes of multiple […]

Ocrevus Helps Preserve Hand and Arm Function in PPMS Patients, Trial Data Show

Treating primary progressive multiple sclerosis (PPMS) patients with Ocrevus (ocrelizumab) can help to preserve strength and function in their hands and the arms, analysis of data from a Phase 3 trial found. The research, “Ocrelizumab reduces progression of upper extremity impairment in patients with primary progressive multiple sclerosis: Findings from the phase III randomized ORATORIO trial,” […]

MS News that Caught My Eye Last Week: Ocrevus in the UK, Environmental Triggers, PPMS Research

NICE Postpones Final Opinion on Adding Ocrevus to Public Health System for PPMS Patients in UK This last-minute reprieve from the agency that dictates which medications may be prescribed for patients of the U.K.’s National Health Service (NHS) is welcome news. Last summer, the National Institute for Health and Care Excellence (NICE) said the benefits […]